Search

Your search keyword '"Ost, P."' showing total 99 results

Search Constraints

Start Over You searched for: Author "Ost, P." Remove constraint Author: "Ost, P." Journal european urology supplements Remove constraint Journal: european urology supplements
99 results on '"Ost, P."'

Search Results

1. PT079 - Which patients should be still considered for late salvage radiotherapy for rising or persistently elevated PSA after radical prostatectomy: Results from a large multi-institutional study

2. Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series

3. Assessing the impact and predictors of other-cause mortality in patients treated with post-prostatectomy salvage radiation therapy in order to avoid possible overtreatment: Results from a large, multi-institutional study

4. There is no way to compensate for a non-timely use of salvage radiation therapy in men with recurrent prostate cancer after radical prostatectomy

5. Assessing the impact and predictors of other-cause mortality in patients treated with post-prostatectomy salvage radiation therapy in order to avoid possible overtreatment: Results from a large, multi-institutional study

6. Randomized phase 1 trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results

7. Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series

8. What is the best definition of biochemical response to salvage radiation therapy in prostate cancer patients treated for PSA rising after radical prostatectomy? Results from a multi-institutional series

9. Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: A multi-institutional analysis

10. Castration-resistant prostate cancer-free survival in the multicentric prospective local treatment of metastatic prostate cancer (LoMP) trial

11. There is no way to compensate for a non-timely use of salvage radiation therapy in men with recurrent prostate cancer after radical prostatectomy

13. Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: a multi-institutional analysis

15. When should salvage radiation therapy be associated with concomitant hormonal therapy in patients affected by prostate cancer? The key role of PSA doubling time

16. What is the optimal field of post-prostatectomy radiation therapy? Long-term results from a multi-institutional study

17. The prognostic role of early PSA response after salvage radiation therapy: Long-term results from a multi-institutional study

19. Which patients should be still considered for late salvage radiotherapy for rising or persistently elevated PSA after radical prostatectomy: Results from a large multi-institutional study

20. Is focal therapy for prostate cancer an attractive option? Results of an international survey from the young academic urologists (YAU) amongst 484 physicians

21. Assessing the need for and the optimal duration of hormonal therapy in association with post-prostatectomy radiation therapy: Results from a multi-institutional study

22. Effect of extended pelvic lymph node dissection on oncologic outcomes in D’Amico intermediate- and high-risk radical prostatectomy patients

23. What is the optimal field of post-prostatectomy radiation therapy? Long-term results from a multi-institutional study

24. The prognostic role of early PSA response after salvage radiation therapy: Long-term results from a multi-institutional study

25. How can we expand active surveillance criteria in patients with low- and intermediate risk prostate cancer without increasing the risk of misclassification: Development of a novel risk calculator

26. Adjuvant versus early salvage radiation therapy in node positive prostate cancer patients: A long-term survival analysis

27. Natural history of patients treated with salvage radiation therapy for rising PSA after radical prostatectomy: A long-term survival analysis

29. More extensive lymph node dissection at radical prostatectomy is associated with improved outcomes after salvage radiotherapy for rising PSA after surgery: A long-term, multi-institutional analysis

30. Assessing the risk of early and late toxicity of post-prostatectomy radiation therapy: A long-term multi-institutional analysis

31. SC189 - Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series

32. SC184 - There is no way to compensate for a non-timely use of salvage radiation therapy in men with recurrent prostate cancer after radical prostatectomy

33. SC183 - Assessing the impact and predictors of other-cause mortality in patients treated with post-prostatectomy salvage radiation therapy in order to avoid possible overtreatment: Results from a large, multi-institutional study

36. 772 - Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series

37. 771 - Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: A multi-institutional analysis

38. Stereotactic body radiotherapy for nodal oligorecurrent prostate cancer: A multi-institutional analysis

42. P046 - Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: a multi-institutional analysis

43. P249 - The prognostic role of early PSA response after salvage radiation therapy: Long-term results from a multi-institutional study

44. P248 - When should salvage radiation therapy be associated with concomitant hormonal therapy in patients affected by prostate cancer? The key role of PSA doubling time

45. P251 - What is the optimal field of post-prostatectomy radiation therapy? Long-term results from a multi-institutional study

49. 537 - How can we expand active surveillance criteria in patients with low- and intermediate risk prostate cancer without increasing the risk of misclassification: Development of a novel risk calculator

50. 400 - Assessing the need for and the optimal duration of hormonal therapy in association with post-prostatectomy radiation therapy: Results from a multi-institutional study

Catalog

Books, media, physical & digital resources